DOCSLIB.ORG

A Multilevel Approach to Define the Hierarchical Organisation of Extracellular Matrix Microfibrils

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Multilevel Approach to Define the Hierarchical Organisation of Extracellular Matrix Microfibrils A multilevel approach to define the hierarchical organisation of extracellular matrix microfibrils A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy (PhD) in the School of Biological Sciences in the the Faculty of Biology, Medicine and Health 2016 Alan Robert Francis Godwin List of contents List of contents................................................................................................................ 2 List of figures .................................................................................................................. 6 List of tables ................................................................................................................... 9 List of abbreviations ........................................................................................................ 9 Abstract ........................................................................................................................ 13 Declaration ................................................................................................................... 14 Copyright statement ...................................................................................................... 14 Acknowledgements ....................................................................................................... 15 1 Introduction ............................................................................................................ 16 1.1 Fibrillin microfibrils .................................................................................................. 16 1.1.1 Fibrillin family ................................................................................................... 16 1.1.2 Fibrillin domain organisation ............................................................................ 17 1.1.2.1 Fibrillin unique N-terminal domain ............................................................ 18 1.1.2.2 EGF domains ........................................................................................... 19 1.1.2.3 TB domains .............................................................................................. 19 1.1.2.4 Hybrid domain .......................................................................................... 19 1.1.3 Fibrillin microfibril assembly ............................................................................. 20 1.1.4 Fibrillin microfibril structure .............................................................................. 21 1.1.5 Fibrillin packing models ................................................................................... 23 1.1.6 Fibrillin tissue organisation............................................................................... 26 1.1.7 The fibrillin microenvironment .......................................................................... 27 1.1.7.1 Elastic fibre associated proteins ............................................................... 27 1.1.7.2 Elastin ...................................................................................................... 27 1.1.7.3 Fibulins ..................................................................................................... 28 1.1.7.4 LOX .......................................................................................................... 28 2 1.1.7.5 Elastic fibre assembly ............................................................................... 29 1.1.7.6 Integrins ................................................................................................... 29 1.1.7.7 Proteoglycans ........................................................................................... 30 1.1.7.8 ADAMTS and ADAMTSL .......................................................................... 31 1.1.7.9 MAGPs ..................................................................................................... 32 1.1.7.10 Regulation of growth factor bioavailability ................................................. 33 1.1.7.11 LTBPs ...................................................................................................... 33 1.1.7.12 BMPs ........................................................................................................ 34 1.1.8 Fibrillinopathies ................................................................................................ 34 1.2 Fibrillin summary..................................................................................................... 38 1.3 Collagen VI microfibrils ........................................................................................... 39 1.3.1 Collagen VI α chains ........................................................................................ 39 1.3.2 Collagen VI α chain domain organisation ......................................................... 39 1.3.2.1 Collagen VI helical region ......................................................................... 41 1.3.2.2 Globular domains ..................................................................................... 42 1.3.3 Collagen VI microfibril assembly ...................................................................... 43 1.3.4 Collagen VI microfibril structure ....................................................................... 44 1.3.5 Collagen VI function......................................................................................... 46 1.3.5.1 Collagen VI and the cell surface ............................................................... 47 1.3.5.2 Collagen VI and PCM structure ................................................................ 48 1.3.6 Collagen VI tissue organisation ....................................................................... 48 1.3.7 Collagen VI diseases ....................................................................................... 49 1.3.8 Knockout mouse models of Bethlem myopathy ............................................... 50 1.4 Collagen VI summary ............................................................................................. 50 1.5 Project aims ............................................................................................................ 51 2 Materials and methods .......................................................................................... 53 2.1 Tissue sources ....................................................................................................... 53 2.2 Tissue culture ......................................................................................................... 53 2.3 Microfibril extractions .............................................................................................. 53 2.3.1 Fibrillin tissue microfibrils ................................................................................. 53 2.3.2 Collagen VI tissue microfibrils .......................................................................... 54 3 2.3.3 N6-C5 collagen VI microfibrils .......................................................................... 54 2.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis ................................. 55 2.5 Western blotting ...................................................................................................... 55 2.6 Transmission electron microscopy .......................................................................... 55 2.6.1 The transmission electron microscope ............................................................. 55 2.6.2 Image formation and contrast .......................................................................... 57 2.6.3 Sample preparation ......................................................................................... 58 2.6.4 Single particle 3D reconstruction ..................................................................... 59 2.6.4.1 CTF correction .......................................................................................... 59 2.6.4.2 Alignment ................................................................................................. 59 2.6.4.3 Classification ............................................................................................ 60 2.6.4.4 Determination of particle orientation ......................................................... 60 2.6.4.5 3D reconstruction ..................................................................................... 61 2.7 Negative stain TEM ................................................................................................ 62 2.8 Cryo-TEM ............................................................................................................... 63 2.8.1 Fibrillin microfibrils ........................................................................................... 63 2.8.2 Collagen VI microfibrils .................................................................................... 63 2.9 Single particle averaging and 3D model reconstruction of matrix microfibrils .......... 63 2.9.1 Fibrillin ............................................................................................................. 63 2.9.1.1 Fibrillin sub-models ................................................................................... 66 2.9.2 Collagen VI ...................................................................................................... 66 2.9.2.1 Single bead model .................................................................................... 66 2.9.3 Docking of fibrillin-1
Load more

Recommended publications
  • An Integrative Systems Approach Identifies Novel Candidates in Marfan Syndrome-Related Pathophysiology
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by The Jackson Laboratory: The Mouseion at the JAXlibrary The Jackson Laboratory The Mouseion at the JAXlibrary Faculty Research 2019 Faculty Research 2019 An integrative systems approach identifies novel candidates in Marfan syndrome-related pathophysiology. Raghu Bhushan Lukas Altinbas Marten Jäger Marcin Zaradzki Daniel Lehmann See next page for additional authors Follow this and additional works at: https://mouseion.jax.org/stfb2019 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons Recommended Citation Bhushan, Raghu; Altinbas, Lukas; Jäger, Marten; Zaradzki, Marcin; Lehmann, Daniel; Timmermann, Bernd; Clayton, Nicholas P; Zhu, Yunxiang; Kallenbach, Klaus; Kararigas, Georgios; and Robinson, Peter N, "An integrative systems approach identifies novel candidates in Marfan syndrome-related pathophysiology." (2019). Faculty Research 2019. 76. https://mouseion.jax.org/stfb2019/76 This Article is brought to you for free and open access by the Faculty Research at The ousM eion at the JAXlibrary. It has been accepted for inclusion in Faculty Research 2019 by an authorized administrator of The ousM eion at the JAXlibrary. For more information, please contact [email protected]. Authors Raghu Bhushan, Lukas Altinbas, Marten Jäger, Marcin Zaradzki, Daniel Lehmann, Bernd Timmermann, Nicholas P Clayton, Yunxiang Zhu, Klaus Kallenbach, Georgios Kararigas, and Peter N Robinson This article is available at The ousM eion at the JAXlibrary: https://mouseion.jax.org/stfb2019/76 Received: 20 May 2018 | Revised: 11 December 2018 | Accepted: 13 December 2018 DOI: 10.1111/jcmm.14137 ORIGINAL ARTICLE An integrative systems approach identifies novel candidates in Marfan syndrome‐related pathophysiology Raghu Bhushan1,2 | Lukas Altinbas1 | Marten Jäger1,3 | Marcin Zaradzki4 | Daniel Lehmann1 | Bernd Timmermann5 | Nicholas P.
    [Show full text]
  • Altered Glycosylation in Pancreatic Cancer: Development of New Tumor Markers and Therapeutic Strategies
    ALTERED GLYCOSYLATION IN PANCREATIC CANCER: DEVELOPMENT OF NEW TUMOR MARKERS AND THERAPEUTIC STRATEGIES Pedro Enrique Guerrero Barrado Per citar o enllaçar aquest document: Para citar o enlazar este documento: Use this url to cite or link to this publication: http://hdl.handle.net/10803/671007 ADVERTIMENT. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs. ADVERTENCIA. El acceso a los contenidos de esta tesis doctoral y su utilización debe respetar los derechos de la persona autora. Puede ser utilizada para consulta o estudio personal, así como en actividades o materiales de investigación y docencia en los términos establecidos en el art. 32 del Texto Refundido de la Ley de Propiedad Intelectual (RDL 1/1996).
    [Show full text]
  • Human Microfibrillar-Associated Protein 4 (MFAP4) Gene Promoter
    International Journal of Molecular Sciences Article Human Microfibrillar-Associated Protein 4 (MFAP4) Gene Promoter: A TATA-Less Promoter That Is Regulated by Retinol and Coenzyme Q10 in Human Fibroblast Cells Ying-Ju Lin 1,2, An-Ni Chen 3, Xi Jiang Yin 4, Chunxiang Li 4 and Chih-Chien Lin 3,* 1 School of Chinese Medicine, China Medical University, Taichung 40447, Taiwan; [email protected] 2 Genetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung 40447, Taiwan 3 Department of Cosmetic Science, Providence University, Taichung 43301, Taiwan; [email protected] 4 Advanced Materials Technology Centre, Singapore Polytechnic, Singapore 139651, Singapore; [email protected] (X.J.Y.); [email protected] (C.L.) * Correspondence: [email protected]; Tel.: +886-4-26328001; Fax: +886-4-26311167 Received: 8 October 2020; Accepted: 4 November 2020; Published: 9 November 2020 Abstract: Elastic fibers are one of the major structural components of the extracellular matrix (ECM) in human connective tissues. Among these fibers, microfibrillar-associated protein 4 (MFAP4) is one of the most important microfibril-associated glycoproteins. MFAP4 has been found to bind with elastin microfibrils and interact directly with fibrillin-1, and then aid in elastic fiber formation. However, the regulations of the human MFAP4 gene are not so clear. Therefore, in this study, we firstly aimed to analyze and identify the promoter region of the human MFAP4 gene. The results indicate that the human MFAP4 promoter is a TATA-less promoter with tissue- and species-specific properties. Moreover, the promoter can be up-regulated by retinol and coenzyme Q10 (coQ10) in Detroit 551 cells.
    [Show full text]
  • An Integrative Systems Approach Identifies Novel Candidates in Marfan Syndrome‐Related Pathophysiology
    Received: 20 May 2018 | Revised: 11 December 2018 | Accepted: 13 December 2018 DOI: 10.1111/jcmm.14137 ORIGINAL ARTICLE An integrative systems approach identifies novel candidates in Marfan syndrome‐related pathophysiology Raghu Bhushan1,2 | Lukas Altinbas1 | Marten Jäger1,3 | Marcin Zaradzki4 | Daniel Lehmann1 | Bernd Timmermann5 | Nicholas P. Clayton6 | Yunxiang Zhu6 | Klaus Kallenbach4,7 | Georgios Kararigas1,8 | Peter N. Robinson1,5,9 1Charité University Hospital, Berlin, Germany Abstract 2Yenepoya Research Centre, Yenepoya Marfan syndrome (MFS) is an autosomal dominant genetic disorder caused by (Deemed to be University), Deralakatte, mutations in the FBN1 gene. Although many peripheral tissues are affected, aortic Mangalore, India ‐ 3Berlin Institute of Health (BIH) Core complications, such as dilation, dissection and rupture, are the leading causes of MFS Genomics Facility, Charité, University related mortality. Aberrant TGF‐beta signalling plays a major role in the pathophysiol- Medical Center, Berlin, Germany ogy of MFS. However, the contributing mechanisms are still poorly understood. Here, 4Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany we aimed at identifying novel aorta‐specific pathways involved in the pathophysiology 5Max Planck Institute for Molecular of MFS. For this purpose, we employed the Fbn1 under‐expressing mgR/mgR mouse Genetics, Berlin, Germany model of MFS. We performed RNA‐sequencing of aortic tissues of 9‐week‐old mgR/ 6Sanofi Genzyme, Framingham, Massachusetts mgR mice compared with wild‐type (WT) mice. With a false discovery rate <5%, our 7Department of Cardiac Surgery, INCCI analysis revealed 248 genes to be differentially regulated including 20 genes previ- HaerzZenter, Luxembourg, Luxembourg ously unrelated with MFS‐related pathology. Among these, we identified Igfbp2, Ccl8, 8DZHK (German Centre for Cardiovascular Research), Berlin, Germany Spp1, Mylk2, Mfap4, Dsp and H19.
    [Show full text]
  • Mechanistic Understanding of Nanoparticles' Interactions With
    Engin et al. Particle and Fibre Toxicology (2017) 14:22 DOI 10.1186/s12989-017-0199-z REVIEW Open Access Mechanistic understanding of nanoparticles’ interactions with extracellular matrix: the cell and immune system Ayse Basak Engin1, Dragana Nikitovic2, Monica Neagu3, Petra Henrich-Noack4, Anca Oana Docea5, Mikhail I. Shtilman6, Kirill Golokhvast7 and Aristidis M. Tsatsakis7,8* Abstract Extracellular matrix (ECM) is an extraordinarily complex and unique meshwork composed of structural proteins and glycosaminoglycans. The ECM provides essential physical scaffolding for the cellular constituents, as well as contributes to crucial biochemical signaling. Importantly, ECM is an indispensable part of all biological barriers and substantially modulates the interchange of the nanotechnology products through these barriers. The interactions of the ECM with nanoparticles (NPs) depend on the morphological characteristics of intercellular matrix and on the physical characteristics of the NPs and may be either deleterious or beneficial. Importantly, an altered expression of ECM molecules ultimately affects all biological processes including inflammation. This review critically discusses the specific behavior of NPs that are within the ECM domain, and passing through the biological barriers. Furthermore, regenerative and toxicological aspects of nanomaterials are debated in terms of the immune cells-NPs interactions. Keywords: Extracellular matrix, Nanoparticle, Inflammation, Biological barriers Background defines tissue properties. Concisely, the ECM compo- Extracellular matrix (ECM) represents a complex network nents provide the mechanical and structural support as of variously modified proteins and the glycosaminoglycan, they define the size, morphology and strength of tissues hyaluronan, highly organized in a form of a suprastructure in vivo [4]. Additionally, this polymer-based micro- which ultimately constitutes the cell microenvironment environment is also important during growth, develop- [1].
    [Show full text]
  • Basic Composition and Alterations in Chronic Lung Disease
    BACK TO BASICS | LUNG DISEASE The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease Gerald Burgstaller1, Bettina Oehrle1, Michael Gerckens1, Eric S. White 2, Herbert B. Schiller1 and Oliver Eickelberg 3 Affiliations: 1Comprehensive Pneumology Center, University Hospital of the Ludwig-Maximilians-University Munich and Helmholtz Zentrum München, Member of the German Center for Lung Research, Munich, Germany. 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. 3Division of Respiratory Sciences and Critical Care Medicine, University of Colorado, Denver, CO, USA. Correspondence: Gerald Burgstaller, Comprehensive Pneumology Center, Helmholtz Center Munich, Ludwig Maximilians University Munich, University Hospital Grosshadern, Max-Lebsche-Platz 31, Munich, Germany. E-mail: [email protected] @ERSpublications Molecular/biomechanical alterations within ECM in chronic lung diseases direct cellular function/ differentiation http://ow.ly/9GrY30c0LJG Cite this article as: Burgstaller G, Oehrle B, Gerckens M, et al. The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. Eur Respir J 2017; 50: 1601805 [https://doi. org/10.1183/13993003.01805-2016]. ABSTRACT The pulmonary extracellular matrix (ECM) determines the tissue architecture of the lung, and provides mechanical stability and elastic recoil, which are essential for physiological lung function. Biochemical and biomechanical signals initiated by the ECM direct cellular function and differentiation, and thus play a decisive role in lung development, tissue remodelling processes and maintenance of adult homeostasis. Recent proteomic studies have demonstrated that at least 150 different ECM proteins, glycosaminoglycans and modifying enzymes are expressed in the lung, and these assemble into intricate composite biomaterials.
    [Show full text]
  • Table of Contents
    10th INTERNATIONAL RESEARCH SYMPOSIUM ON MARFAN SYNDROME AND RELATED DISORDERS TABLE OF CONTENTS Welcome 1 Program 3 Thursday, May 3, 2018 3 Friday, May 4, 2018 6 Saturday, May 5, 2018 10 Poster Presentation List 13 Abstracts of Oral Presentations 19 Abstracts of Poster Presentations 87 General Information 138 Author Index 139 10th INTERNATIONAL RESEARCH SYMPOSIUM ON MARFAN SYNDROME AND RELATED DISORDERS ORGANIZING COMMITTEE Josephine Grima, PhD Janneke Timmermans, MD The Marfan Foundation Radboud University Medical Center Port Washington, NY, USA Nijmegen, The Netherlands Ine Woustra Marlies J.E. Kempers, MD, PhD Contactgroep The Netherlands Radboud University Medical Center Silvolde, The Netherlands Nijmegen, The Netherlands PROGRAM COMMITTEE Suneel S. Apte, MBBS, D.Phil. Arturo Evangelista, MD Lerner Research Institute, Hospital Universitario Vall d’Hebron Cleveland Clinic Barcelona, Spain Cleveland, OH, USA Maarten Groenink, MD, PhD Alan Braverman, MD Academic Medical Center Washington University Amsterdam, The Netherlands St. Louis, MO, USA Rachel Kuchtey, MD, PhD Peter Byers, MD Vanderbilt University Medical Center University of Washington School Nashville, TN, USA of Medicine Seattle, WA, USA Bart Loeys, MD, PhD University of Antwerp Duke Cameron, MD Antwerp, Belgium Massachusetts General Hospital Boston, MA, USA Daniel B. Rifkin, PhD NYU Medical Center Julie De Backer, MD, PhD New York, USA University Hospital Ghent Ghent, Belgium Hal Dietz, MD Johns Hopkins University School of Medicine Baltimore, MD, USA 10th INTERNATIONAL RESEARCH SYMPOSIUM ON MARFAN SYNDROME AND RELATED DISORDERS 1 Words of welcome... On behalf of the local and program organizing committee, we would like to welcome you to Amsterdam, The Netherlands for the 10th International Research Symposium on Marfan Syndrome and Related Disorders.
    [Show full text]
  • The Molecular Genetics of Marfan Syndrome and Related Disorders
    The molecular genetics of Marfan syndrome and related disorders. Peter Robinson, Emilio Arteaga-Solis, Clair Baldock, Gwenaëlle Collod-Béroud, Patrick Booms, Anne de Paepe, Harry Dietz, Gao Guo, Penny Handford, Daniel Judge, et al. To cite this version: Peter Robinson, Emilio Arteaga-Solis, Clair Baldock, Gwenaëlle Collod-Béroud, Patrick Booms, et al.. The molecular genetics of Marfan syndrome and related disorders.. Journal of Medical Genetics, BMJ Publishing Group, 2006, 43 (10), pp.769-87. 10.1136/jmg.2005.039669. inserm-00143572 HAL Id: inserm-00143572 https://www.hal.inserm.fr/inserm-00143572 Submitted on 20 Dec 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Rev 7.51n/W (Jan 20 2003) Journal of Medical Genetics mg39669 Module 2 17/4/06 12:55:12 Topics: 11; 259 1 REVIEW The molecular genetics of Marfan syndrome and related disorders P Robinson, E Arteaga-Solis, C Baldock, G Collod-Be´roud, P Booms, A De Paepe, H C Dietz, G Guo, P A Handford, D P Judge, C M Kielty, B Loeys, D M Milewicz, A Ney, F Ramirez, D P Reinhardt, K Tiedemann, P Whiteman, M Godfrey .
    [Show full text]
  • High Plasma Microfibrillar-Associated Protein 4 Is Associated with Reduced Surgical Repair in Abdominal Aortic Aneurysms
    University of Southern Denmark High plasma microfibrillar-associated protein 4 is associated with reduced surgical repair in abdominal aortic aneurysms Lindholt, Jes Sanddal; Madsen, Mathilde; Kirketerp-Møller, Katrine Lindequist; Schlosser, Anders; Kristensen, Katrine Lawaetz; Andersen, Carsten Behr; Sorensen, Grith Lykke Published in: Journal of Vascular Surgery DOI: 10.1016/j.jvs.2019.08.253 Publication date: 2020 Document version: Final published version Document license: CC BY-NC-ND Citation for pulished version (APA): Lindholt, J. S., Madsen, M., Kirketerp-Møller, K. L., Schlosser, A., Kristensen, K. L., Andersen, C. B., & Sorensen, G. L. (2020). High plasma microfibrillar-associated protein 4 is associated with reduced surgical repair in abdominal aortic aneurysms. Journal of Vascular Surgery, 71(6), 1921-1929. https://doi.org/10.1016/j.jvs.2019.08.253 Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to [email protected]
    [Show full text]
  • Fibrillin-2 Is a Key Mediator of Smooth Muscle Extracellular Matrix Homeostasis During Mouse Tracheal Tubulogenesis
    ORIGINAL ARTICLE BASIC SCIENCE Fibrillin-2 is a key mediator of smooth muscle extracellular matrix homeostasis during mouse tracheal tubulogenesis Wenguang Yin1,8, Hyun-Taek Kim1, ShengPeng Wang2,3, Felix Gunawan1, Rui Li2, Carmen Buettner1, Beate Grohmann1, Gerhard Sengle4,5, Debora Sinner6, Stefan Offermanns2,7 and Didier Y.R. Stainier1,8 Affiliations: 1Max Planck Institute for Heart and Lung Research, Dept of Developmental Genetics, Bad Nauheim, Germany. 2Max Planck Institute for Heart and Lung Research, Dept of Pharmacology, Bad Nauheim, Germany. 3Cardiovascular Research Center, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an, China. 4Center for Biochemistry, Medical Faculty, University of Cologne, Cologne, Germany. 5Center for Molecular Medicine Cologne (CMMC), Cologne, Germany. 6Division of Neonatology and Pulmonary Biology, CCHMC, University of Cincinnati, College of Medicine Cincinnati, OH, USA. 7Center for Molecular Medicine, Goethe University, Frankfurt, Germany. 8W. Yin and D.Y.R. Stainier are joint senior authors. Correspondence: Didier Y.R. Stainier, Dept of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany. E-mail: [email protected] @ERSpublications Defects in extracellular matrix formation lead to altered airway smooth muscle organisation in tracheal stenosis, and pharmacological decrease of p38 phosphorylation or matrix metalloproteinase activity partially attenuates these defects http://ow.ly/4zku30mWub3 Cite this article as: Yin W, Kim H-T, Wang SP, et al. Fibrillin-2 is a key mediator of smooth muscle extracellular matrix homeostasis during mouse tracheal tubulogenesis. Eur Respir J 2019; 53: 1800840 [https://doi.org/10.1183/13993003.00840-2018]. ABSTRACT Epithelial tubes, comprised of polarised epithelial cells around a lumen, are crucial for organ function.
    [Show full text]
  • Essential Role of Microfibrillar-Associated Protein 4 In
    Essential role of microfibrillar-associated protein 4 in human cutaneous SUBJECT AREAS: PATTERN FORMATION homeostasis and in its photoprotection DEVELOPMENT Shinya Kasamatsu1, Akira Hachiya1, Tsutomu Fujimura1, Penkanok Sriwiriyanont2, Keiichi Haketa1, BIOMARKERS Marty O. Visscher3, William J. Kitzmiller4, Alexander Bello5, Takashi Kitahara1, Gary P. Kobinger5 EXTRA-CELLULAR MATRIX & Yoshinori Takema1 Received 1Biological Science Laboratories, Kao Corporation, Haga, Tochigi, 321–3497, Japan, 2Department of Biomedical Engineering, 5 August 2011 University of Cincinnati, Cincinnati, OH 45267, USA, 3Division of Neonatology and Skin Sciences Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 45229, USA, 4Department of Surgery, University of Cincinnati, Cincinnati, OH, 45267, Accepted 5 8 November 2011 USA, Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 3R2, Canada. Published 22 November 2011 UVB-induced cutaneous photodamage/photoaging is characterized by qualitative and quantitative deterioration in dermal extracellular matrix (ECM) components such as collagen and elastic fibers. Disappearance of microfibrillar-associated protein 4 (MFAP-4), a possible limiting factor for cutaneous Correspondence and elasticity, was documented in photoaged dermis, but its function is poorly understood. To characterize its requests for materials possible contribution to photoprotection, MFAP-4 expression was
    [Show full text]
  • Proteomic Comparison Between Abdominal and Thoracic Aortic Aneurysms
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 33: 1035-1047, 2014 Proteomic comparison between abdominal and thoracic aortic aneurysms KEN-ICHI MATSUMOTO1, KAZUMI SATOH1, TOMOKO MANIWA1, TETSUYA TANAKA2, HIDEKI OKUNISHI2 and TEIJI ODA3 1Department of Biosignaling and Radioisotope Experiment, Interdisciplinary Center for Science Research, Organization for Research, Shimane University, 2Department of Pharmacology and 3Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Shimane University School of Medicine, Izumo 693-8501, Japan Received September 28, 2013; Accepted January 14, 2014 DOI: 10.3892/ijmm.2014.1627 Abstract. The pathogenesis of abdominal aortic aneurysms Introduction (AAAs) and that of thoracic aortic aneurysms (TAAs) is distinct. In this study, to reveal the differences in their biochemical An aortic aneurysm (AA) is an enlargement which occurs properties, we performed quantitative proteomic analysis of in the aorta, leading to progressive dilatation and ultimate AAAs and TAAs compared with adjacent normal aorta (NA) rupture. According to their anatomical locations, AAs are tissues. The proteomic analysis revealed 176 non-redundant generally classified as abdominal AAs (AAAs) and thoracic differentially expressed proteins in the AAAs and 189 proteins AAs (TAAs), which appear to have distinct pathologies and in the TAAs which were common in at least 5 samples within mechanisms (1). AAAs are much more common (an incidence 7 samples of each. Among the identified proteins, 55 and of at least 3-fold higher) than TAAs (2). The differences in 68 proteins were unique to the AAAs and TAAs, respectively, the physical structure and mechanical stress of abdominal whereas 121 proteins were identified in both the AAAs and and thoracic aortas may also contribute to the disparities in TAAs.
    [Show full text]